The acquisition, which will give Sanofi a combination vaccine for respiratory syncytial virus and human metapneumovirus, ...

The deal seeks to strengthen the drugmaker’s portfolio of respiratory vaccines and help it move on from pipeline setbacks.

The Pasteur Institute in Ho Chi Minh City and Nagasaki University of Japan, both leading facilities in tropical medicine and ...

The French pharma will pay $1.15 billion upfront to buy Vicebio and gain access to non-mRNA vaccine candidates against RSV ...

Paris-based drugmaker Sanofi is acquiring U,K,-based Vicebio to gain its molecular clamp vaccine technology, with the total ...

French pharmaceutical company Sanofi said it is acquiring London-based Vicebio to expand its range of respiratory virus ...

The US Food and Drug Administration(FDA) has granted Fast Track designation to two non-mRNA combination vaccine candidates put forward by Sanofi.

The situation in the US is deeply concerning – for vaccine uptake and for the impacts globally.

The votes on vaccine recommendations are the first move by the panel after Health and Human Services Secretary Robert F. Kennedy Jr. replaced all its members.